Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics... Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.
- Mechanism
- Curator reviewed · 2 references
Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland.
- Primary indication
- Bromotheophylline is used as a diuretic and also, in combination with DB00316, it is used for the relief of temporary water weight gain, bloating, swelling and full feeling associated with the premenstrual and menstrual periods.Curator reviewed · 4 structured indications
- Formula / weight
- C7H7BrN4O2 · 259.063 g/mol (avg)
- First approval
- Canada, 1999
- Also known as
- 8-Bromotheophylline
- Brand names
Resolves to
SKTFQHRVFFOHTQ-UHFFFAOYSA-NSMILESCN1C2=C(NC(Br)=N2)C(=O)N(C)C1=OWhat you can answer from here — as of September 13, 2026
Which other approved drugs treat the same conditions as Bromotheophylline, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account